Effect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left Ventricular Ejection Fraction and Renal Function.
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 164 participants.
Also called NCT05879276
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 164 participants
- Registry
-
NCT05879276
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- France
- Registry status
- Recruiting
Technical summary
Registry record NCT05879276. Randomized; no masking; primary purpose treatment. Start 2024-12-16 (actual); primary completion 2027-03-16 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left Ventricular Ejection Fraction and Renal Function.
- Acronym
- EMPASHOCK
- Condition
- Cardiogenic Shock
- Intervention (Drug)
- Empagliflozin 10 MG
- Lead sponsor
- Central Hospital, Nancy, France
Record details
- Record id
cardio:ct-nct05879276- Content hash
8403ed852c52cf68787f5778a3e1774e2e8184543616c712e5b1f9efa8a8a9ab